Aqua Bio Technology
ISIN: NO0010307135 | Ticker: ABT | LEI: 529900RG33DF0N88RJ88
Country: Norway
Aqua Bio Technology is well into the third phase of its development, providing natural and sustainable ingredients to the cosmetics industry and skincare products and consumers.
ABT developed and commercialized its proprietary enzyme technology based on the salmon’s hatching fluid. The ingredient Aquabeautine XL™ holds several properties attractive to skincare product manufacturers. The technology has since 2012 been licensed to a U.S. based skincare company.
The second step in developing ABT was establishing the Company as a center for commercialization of third party biotechnology. ABT has collaborated with several technology owners since 2012 and is developing and commercializing natural and sustainable skincare ingredients based on e.g. algae and olives for the industry.
2000
Served areaWorldwide
HeadquartersFornebuveien 37, 1366 Lysaker – Norway
| Line item in (nok) | 01.01.2020 | 01.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|---|
| Assets | N/A | 16,237,927.00 | 34,429,500.00 | 67,202,711.00 |
| Noncurrent Assets | N/A | 9,793,674.00 | 12,571,167.00 | 54,433,289.00 |
| Property Plant And Equipment | N/A | 528,397.00 | 287,197.00 | 145,997.00 |
| Deferred Tax Assets | N/A | 0.00 | 0.00 | 0.00 |
| Current Assets | N/A | 6,444,253.00 | 21,858,333.00 | 12,769,421.00 |
| Inventories | N/A | 810,000.00 | 5,691,893.00 | 8,304,804.00 |
| Trade And Other Current Receivables | N/A | 205,098.00 | 2,810,078.00 | 2,603,137.00 |
| Cash and cash equivalents | 6,875,656.00 | 5,429,155.00 | 13,356,362.00 | 1,861,481.00 |
| Equity And Liabilities | N/A | 16,237,927.00 | 34,429,500.00 | 67,202,711.00 |
| Equity | 7,322,955.00 | 8,321,078.00 | 18,706,420.00 | 1,860,516.00 |
| Issued Capital | N/A | 45,998,428.00 | 51,559,480.00 | 51,684,480.00 |
| Treasury Shares | N/A | 31,950.00 | 31,950.00 | 31,950.00 |
| Liabilities | N/A | 7,916,849.00 | 15,723,080.00 | 65,342,195.00 |
| Noncurrent Liabilities | N/A | 4,590,877.00 | 3,665,438.00 | 40,518,847.00 |
| Noncurrent Provisions | N/A | N/A | 3,665,438.00 | 37,533,075.00 |
| Deferred Tax Liabilities | N/A | N/A | 0.00 | 2,315,405.00 |
| Other Noncurrent Financial Liabilities | N/A | 3,485,238.00 | 3,665,438.00 | N/A |
| Current Liabilities | N/A | 3,325,972.00 | 12,057,642.00 | 24,823,348.00 |
| Current Provisions | N/A | N/A | 175,350.00 | 1,508,174.00 |
| Trade And Other Current Payables | N/A | N/A | 4,759,096.00 | 7,071,221.00 |
| Trade And Other Current Payables To Trade Suppliers | N/A | 989,313.00 | 2,275,344.00 | N/A |
| Current Tax Liabilities Current | N/A | N/A | 0.00 | 9,223.00 |
| Other Current Financial Liabilities | N/A | 62,987.00 | 175,350.00 | N/A |
| Line item in (nok) | 01.01.2020/ 01.01.2021 |
01.01.2021/ 01.01.2022 |
01.01.2022/ 01.01.2023 |
|---|---|---|---|
| Revenue | 444,376.00 | 1,559,703.00 | 7,016,752.00 |
| Other Income | 368,251.00 | 415,885.00 | 144,532.00 |
| Raw Materials And Consumables Used | 981,486.00 | 951,776.00 | 4,689,013.00 |
| Employee Benefits Expense | 4,935,084.00 | 6,779,132.00 | 9,085,694.00 |
| Depreciation And Amortisation Expense | 112,791.00 | 1,090,120.00 | 1,668,679.00 |
| Profit Loss From Operating Activities | -16,104,721.00 | -17,857,145.00 | -16,367,896.00 |
| Finance Income | 1,475,795.00 | 343,079.00 | 153,294.00 |
| Finance Costs | 324,018.00 | 1,598,698.00 | 2,537,075.00 |
| Profit Loss Before Tax | -14,952,944.00 | -19,112,764.00 | -18,751,677.00 |
| Income Tax Expense Continuing Operations | -249,036.00 | 0.00 | -16,099.00 |
| Profit (loss) | -14,703,908.00 | -19,112,764.00 | -18,735,578.00 |
| Line item in (nok) | 01.01.2020 | 01.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|---|
| Profit (loss) | N/A | -14,703,908.00 | -19,112,764.00 | -18,735,578.00 |
| Adjustments For Decrease Increase In Inventories | N/A | 0.00 | -4,881,893.00 | -935,436.00 |
| Adjustments For Increase Decrease In Trade Account Payable | N/A | 202,737.00 | 1,286,031.00 | 1,767,533.00 |
| Adjustments For Depreciation And Amortisation Expense | N/A | 112,791.00 | 1,090,120.00 | 1,668,679.00 |
| Adjustments For Sharebased Payments | N/A | 546,031.00 | 1,795,509.00 | 1,541,296.00 |
| Interest Received Classified As Operating Activities | N/A | 2,741.00 | 0.00 | 2,212.00 |
| Cash Flows From Used In Operating Activities | N/A | -13,335,007.00 | -20,969,382.00 | -15,448,936.00 |
| Cash Flows Used In Obtaining Control Of Subsidiaries Or Other Businesses Classified As Investing Activities | N/A | 3,131,800.00 | 1,537,725.00 | 4,090,902.00 |
| Cash Flows From Used In Investing Activities | N/A | -3,267,488.00 | -5,405,339.00 | -4,090,902.00 |
| Proceeds From Issuing Shares | N/A | 15,156,000.00 | 27,702,598.00 | 350,000.00 |
| Proceeds From Borrowings Classified As Financing Activities | N/A | 0.00 | 7,700,000.00 | 7,800,000.00 |
| Repayments Of Borrowings Classified As Financing Activities | N/A | 0.00 | 1,100,000.00 | 0.00 |
| Payments Of Lease Liabilities Classified As Financing Activities | N/A | N/A | 0.00 | 60,975.00 |
| Interest Paid Classified As Financing Activities | N/A | 6.00 | 670.00 | 44,067.00 |
| Cash Flows From Used In Financing Activities | N/A | 15,155,994.00 | 34,301,928.00 | 8,044,957.00 |
| Increase (decrease) in cash and cash equivalents before effect of exchange rate changes | N/A | -1,446,501.00 | 7,927,207.00 | -11,494,881.00 |
| Effect Of Exchange Rate Changes On Cash And Cash Equivalents | N/A | 0.00 | 0.00 | 0.00 |
| Cash and cash equivalents | 6,875,656.00 | 5,429,155.00 | 13,356,362.00 | 1,861,481.00 |
Please note that some sums might not add up.
NO0010307135
LEI529900RG33DF0N88RJ88
SectorKeep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.